The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential
Rafael Contreras‐López, Roberto Elizondo‐Vega, Noymar Luque‐Campos, Marı́a José Torres, Carolina Pradenas, Gautier Téjédor, María José Paredes-Martínez, Ana María Vega-Letter, Mauricio Campos‐Mora, Yandi Rigual-Gonzalez, Karina Oyarce, Magdiel Salgado, Christian Jørgensen, Maroun Khoury, María de los Ángeles García, Claudia Altamirano, Farida Djouad, Patricia Luz‐Crawford
Abstract
Altogether, our findings show that AMPK-dependent glycolytic reprogramming of MSC using an ATP synthase inhibitor contributes to their immunosuppressive and therapeutic functions, and suggest that pro-glycolytic drugs might be used to improve MSC-based therapy.
Topics & Concepts
AMPKMesenchymal stem cellGlycolysisATP synthaseChemistryStem cellCell biologyCancer researchEnzymeBiologyBiochemistryProtein kinase AMesenchymal stem cell researchAutophagy in Disease and TherapyEpigenetics and DNA Methylation